The Post COVID-19 pulmonary fibrosis
Conditions
Interventions
Chinese plus western medicine group:Treatment of JiajianHuaxian Formula combination with Prednisone acetate and acetylcysteine tablet.
Western medicine group:Treatment of Prednisone acetate and acetylcysteine tablet.
Chinese medicine group:
Sponsors
Dongfang Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1) In line with the diagnostic criteria of he Post COVID-19 pulmonary fibrosis. 2)Two months following the diagnosis of the Post COVID-19 pulmonary fibrosis, the lung CT scan continues to display indications of pulmonary interstitial fibrosis. 3)The patient's condition is currently stable. 4)Participants who are 18 years of age or older, of any gender. 5)Join in on this medical study voluntarily.
Exclusion criteria
Exclusion criteria: 1)Patients in acute exacerbation. 2)Other known causes of interstitial lung disease. 3)One month before being selected, use pirfenidone and nintedanib.. 4)Pregnant or lactating women. 5)Patients with severe primary diseases such as cardiovascular, liver, kidneys, nervous system, and other organs. 6)Patients with mentally ill or concomitant infectious diseases. 7)Patients who cannot undergo clinical observation. 8)Patients who have participated in other clinical studies within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest HRCT scoring;Symptom Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Medical Research Council Dyspnoea Scale;Pulmonary function tests;St. George's Respiratory Questionnaire;Fatigue Assessment Scale;Inflammatory indexes and fibrosis indexes; | — |
Countries
China
Contacts
Public ContactZhang Xiaomei
Dongfang Hospital Beijing University of Chinese Medicine
Outcome results
None listed